Anila Lingamneni Haemonetics Corp (HAE) insider trading activity

Anila Lingamneni is EVP, Chief Technology Officer of HAEMONETICS CORP. Currently has a direct ownership of 21,331 shares of HAE, which is worth approximately $1.65 Million. The most recent transaction as insider was on Jul 12, 2024, when has been sold 79 shares (Common Stock) at a price of $90.0 per share, resulting in proceeds of $7,110. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 21.3K

0% 3M change

47.16% 12M change

Total Value Held $1.65 Million

Anila Lingamneni Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jul 12 2024	SELL Open market or private sale	$7,110 $90.0 p/Share	79 Reduced 0.37%	21,331 Common Stock
Jul 11 2024	SELL Open market or private sale	$192,240 $90.0 p/Share	2,136 Reduced 9.07%	21,410 Common Stock
May 28 2024	SELL Payment of exercise price or tax liability	$505,358 $95.73 p/Share	5,279 Reduced 18.31%	23,546 Common Stock
May 28 2024	BUY Grant, award, or other acquisition	-	14,140 Added 32.91%	28,825 Common Stock
May 17 2024	SELL Payment of exercise price or tax liability	$33,409 $95.73 p/Share	349 Reduced 3.0%	11,291 Common Stock
May 17 2024	BUY Grant, award, or other acquisition	-	3,394 Added 18.77%	14,685 Common Stock
May 16 2024	SELL Payment of exercise price or tax liability	$30,146 $94.8 p/Share	318 Reduced 2.66%	11,640 Common Stock
May 15 2024	SELL Payment of exercise price or tax liability	$32,517 $96.49 p/Share	337 Reduced 2.74%	11,958 Common Stock
May 06 2024	SELL Open market or private sale	$218,975 $95.0 p/Share	2,305 Reduced 15.79%	12,295 Common Stock
Apr 15 2024	SELL Payment of exercise price or tax liability	$15,617 $84.88 p/Share	184 Reduced 1.27%	14,311 Common Stock
Sep 11 2023	SELL Open market or private sale	$207,450 $90.0 p/Share	2,305 Reduced 13.72%	14,495 Common Stock
May 30 2023	SELL Open market or private sale	$191,992 $83.33 p/Share	2,304 Reduced 12.06%	16,800 Common Stock
May 18 2023	SELL Payment of exercise price or tax liability	$115,425 $83.34 p/Share	1,385 Reduced 6.76%	19,104 Common Stock
May 16 2023	SELL Payment of exercise price or tax liability	$28,368 $89.21 p/Share	318 Reduced 1.53%	20,489 Common Stock
May 15 2023	BUY Grant, award, or other acquisition	-	3,364 Added 13.92%	20,807 Common Stock
Apr 14 2023	SELL Payment of exercise price or tax liability	$14,921 $84.78 p/Share	176 Reduced 1.02%	17,146 Common Stock
May 19 2022	SELL Open market or private sale	$81,794 $59.1 p/Share	1,384 Reduced 7.4%	17,322 Common Stock
May 16 2022	BUY Grant, award, or other acquisition	-	4,340 Added 18.83%	18,706 Common Stock
Apr 18 2022	SELL Open market or private sale	$10,688 $56.55 p/Share	189 Reduced 1.33%	14,013 Common Stock
May 19 2021	SELL Open market or private sale	$5,077 $55.19 p/Share	92 Reduced 0.64%	14,202 Common Stock
May 18 2021	BUY Grant, award, or other acquisition	-	10,605 Added 42.59%	14,294 Common Stock
Apr 16 2021	SELL Open market or private sale	$20,305 $119.44 p/Share	170 Reduced 4.7%	3,444 Common Stock

Anila Lingamneni

EVP, Chief Technology Officer

Boston, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells HAE shares.

Notify only if

Value

Insider Trading

Get notified when an Haemonetics Corp insider buys or sells HAE shares.

Notify only if

Operation

Value

Type

News

Receive news related to HAEMONETICS CORP

Track Activities on HAE

Account